98 related articles for article (PubMed ID: 21736623)
1. An open-label, dose-escalating phase I study of elsamitrucin (SPI 28090) in treatment of malignant solid tumors in dogs.
Fiocchi SC; Selting KA; Rosenberg MP; Kolli P; Lenaz G; Henry C
J Vet Intern Med; 2011; 25(4):897-902. PubMed ID: 21736623
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial and clinical pharmacology of elsamitrucin.
Raber MN; Newman RA; Newman BM; Gaver RC; Schacter LP
Cancer Res; 1992 Mar; 52(6):1406-10. PubMed ID: 1540949
[TBL] [Abstract][Full Text] [Related]
3. Phase I study to determine the maximal tolerated dose and dose-limiting toxicities of orally administered idarubicin in dogs with lymphoma.
Vail DM; Husbands BD; Kamerling SG; Simpson H; Kurzman ID; McDonnell A
J Vet Intern Med; 2012; 26(3):608-13. PubMed ID: 22404399
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma.
Allen SL; Schacter LP; Lichtman SM; Bukowski R; Fusco D; Hensley M; O'Dwyer P; Mittelman A; Rosenbloom B; Huybensz S
Invest New Drugs; 1996; 14(2):213-7. PubMed ID: 8913843
[TBL] [Abstract][Full Text] [Related]
5. An open-label phase 1 dose-escalation clinical trial of a single intravenous administration of gemcitabine in dogs with advanced solid tumors.
Marconato L; Finotello R; Bonfanti U; Dacasto M; Beatrice L; Pizzoni S; Leone VF; Balestra G; Furlanello T; Rohrer Bley C; Aresu L
J Vet Intern Med; 2015; 29(2):620-5. PubMed ID: 25818216
[TBL] [Abstract][Full Text] [Related]
6. Use of epothilone B (patupilone) in refractory lymphoma and advanced solid tumors in dogs.
Meier V; Geigy C; Grosse N; McSheehy P; Rohrer Bley C
J Vet Intern Med; 2013; 27(1):120-5. PubMed ID: 23205945
[TBL] [Abstract][Full Text] [Related]
7. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
Wouda RM; Hocker SE; Higginbotham ML
Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
[TBL] [Abstract][Full Text] [Related]
8. Preclinical study of dolastatin-10 in dogs with spontaneous neoplasia.
Thamm DH; MacEwen EG; Phillips BS; Hershey AE; Burgess KM; Pettit GR; Vail DM
Cancer Chemother Pharmacol; 2002 Mar; 49(3):251-5. PubMed ID: 11935218
[TBL] [Abstract][Full Text] [Related]
9. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.
Mamot C; Ritschard R; Wicki A; Stehle G; Dieterle T; Bubendorf L; Hilker C; Deuster S; Herrmann R; Rochlitz C
Lancet Oncol; 2012 Dec; 13(12):1234-41. PubMed ID: 23153506
[TBL] [Abstract][Full Text] [Related]
10. Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.
Pellin MA; Wouda RM; Robinson K; Tsimbas K; Kurzman ID; Biller BJ; Vail DM
Vet Comp Oncol; 2017 Sep; 15(3):919-931. PubMed ID: 27146577
[TBL] [Abstract][Full Text] [Related]
11. An open-label dose escalation study evaluating tolerability and safety of a single 5-days course of temozolomide in dogs with advanced cancer.
Marconato L; Rohrer Bley C; Leone VF; Finotello R
Vet Comp Oncol; 2020 Dec; 18(4):838-842. PubMed ID: 32510792
[TBL] [Abstract][Full Text] [Related]
12. Toxicoses associated with the administration of mitoxantrone to dogs with malignant tumors: a dose escalation study.
Ogilvie GK; Moore AS; Chen C; Ciekot PA; Atwater SW; Bergman PJ; Walters LM
J Am Vet Med Assoc; 1994 Aug; 205(4):570-3. PubMed ID: 7961092
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of satraplatin in dogs with spontaneously occurring malignant tumors.
Selting KA; Wang X; Gustafson DL; Henry CJ; Villamil JA; McCaw DL; Tate D; Beittenmiller M; Garnett C; Robertson JD
J Vet Intern Med; 2011; 25(4):909-15. PubMed ID: 21564292
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing dogs.
McEntee MC; Rassnick KM; Lewis LD; Zgola MM; Beaulieu BB; Balkman CE; Page RL
Am J Vet Res; 2006 Jun; 67(6):1057-62. PubMed ID: 16740102
[TBL] [Abstract][Full Text] [Related]
15. Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors.
Vail DM; Kravis LD; Cooley AJ; Chun R; MacEwen EG
Cancer Chemother Pharmacol; 1997; 39(5):410-6. PubMed ID: 9054954
[TBL] [Abstract][Full Text] [Related]
16. Phase I dose escalation of single-agent vinblastine in dogs.
Bailey DB; Rassnick KM; Kristal O; Chretin JD; Balkman CE
J Vet Intern Med; 2008; 22(6):1397-402. PubMed ID: 19000250
[TBL] [Abstract][Full Text] [Related]
17. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation.
Thamm DH; Kurzman ID; King I; Li Z; Sznol M; Dubielzig RR; Vail DM; MacEwen EG
Clin Cancer Res; 2005 Jul; 11(13):4827-34. PubMed ID: 16000580
[TBL] [Abstract][Full Text] [Related]
18. Tolerability of metronomic administration of lomustine in dogs with cancer.
Tripp CD; Fidel J; Anderson CL; Patrick M; Pratt C; Sellon R; Bryan JN
J Vet Intern Med; 2011; 25(2):278-84. PubMed ID: 21314727
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of elsamitrucin in non-small cell lung cancer.
Goss G; Letendre F; Stewart D; Shepherd F; Schacter L; Hoogendoorn P; Eisenhauer E
Invest New Drugs; 1994; 12(4):315-7. PubMed ID: 7775132
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE
Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]